Core Viewpoint - Novo Nordisk (NVO.US) reported a strong financial performance for 2025, with total sales reaching 309.1 billion Danish Krone, reflecting a 10% growth at constant exchange rates [1] Group 1: Financial Performance - Total sales for the year amounted to 309.1 billion Danish Krone, with a 10% increase when adjusted for fixed exchange rates [1] - Sales of the entire semaglutide product line reached 228.288 billion Danish Krone [1] - The sales figures for the diabetes treatment semaglutide injection Ozempic (known as 诺和泰 in China) were 127.089 billion Danish Krone, while the weight loss version Wegovy (known as 诺和盈 in China) generated 79.106 billion Danish Krone [1] - The oral formulation of semaglutide (known as 诺和忻 in China) achieved sales of 22.093 billion Danish Krone [1] Group 2: Product Developments - Wegovy tablets, which are administered once daily at a dosage of 25mg, were launched in the U.S. on January 5, with a total weekly prescription volume reaching approximately 50,000 [1] - Novo Nordisk has submitted a supplemental new drug application to the FDA for the 7.2mg version of the weight loss semaglutide injection [1] - The company is also anticipating approval results for next-generation therapies, including Mim8 for hemophilia treatment and CagriSema for obesity treatment [1] Group 3: Market Position - Novo Nordisk holds a leading position in the GLP-1 and insulin markets for diabetes treatment in the Greater China region [1] - The company continues to experience high growth in the obesity and rare disease markets [1]

Core Viewpoint - Merck's (MRK.US) latest quarterly performance report and future outlook fell short of market expectations, primarily due to challenges faced by its HPV vaccine Gardasil, which is expected to struggle in the Chinese market, overshadowing strong growth from other products like Keytruda and new drugs [1][2]. Financial Performance - In Q4, Merck reported total sales of approximately $16.4 billion, a 5% year-over-year increase, exceeding analyst expectations of about $16.2 billion [2]. - Non-GAAP net profit for the quarter was approximately $5.088 billion, reflecting a 16% year-over-year growth, with adjusted earnings per share at $2.04, slightly above analyst forecasts [2]. - Gardasil's sales in Q4 were approximately $1.03 billion, down about 35% year-over-year, attributed to global economic uncertainties and competitive pressures [3]. Product Challenges - Gardasil is facing significant challenges in both the Chinese market, where demand has sharply declined, and in the U.S., where health officials have recommended reducing vaccination doses [2][3]. - Merck has paused Gardasil shipments to China until the end of 2025, not factoring any shipments in its 2026 guidance [1]. Growth Opportunities - Despite Gardasil's challenges, Merck is experiencing growth in other areas, including a new pneumonia vaccine and the rare disease drug Winrevair, which saw a 133% increase in Q4 sales [4]. - Winrevair achieved sales of approximately $467 million in Q4, exceeding analyst expectations [4]. Strategic Initiatives - Merck is preparing for potential price reductions and competition for its top-selling cancer drug Keytruda, which faces patent expiration in 2028 [5][6]. - The company is actively seeking significant acquisition opportunities, with CEO Robert Davis indicating a focus on strategic acquisitions to bolster its drug pipeline [6][8]. Future Outlook - Merck's management is prioritizing oncology treatment innovations and plans to diversify its cancer product line beyond Keytruda [8][9]. - The company is exploring new mechanisms in immunotherapy and potential acquisitions in chronic disease treatments, particularly in COPD and metabolic disorders [9].

Group 1 - The core point of the article highlights the recent surge in newly launched ETFs, with significant investments from institutional players like China Shipbuilding Group Investment Co., which purchased 100 million yuan in the Fortune China Securities Intelligent Shipbuilding Industry ETF [2][3] - The Fortune China Securities Intelligent Shipbuilding Industry ETF is the first ETF focused on shipbuilding, comprising 40 representative listed companies in the shipbuilding industry, reflecting the overall performance of the sector [4][5] - As of February 2, 2023, the top ten holdings of the ETF include major companies such as China Power, China Shipbuilding, and China Ship Defense, indicating a strong focus on the industrial sector [5][7] Group 2 - Recent data shows a significant outflow from broad-based ETFs, with a net outflow of 16.349 billion yuan on February 2, 2023, particularly affecting the Southern CSI 500 ETF and Huatai-PB CSI 300 ETF [10] - In contrast, certain thematic industry ETFs have attracted substantial inflows, with the Guotai Communication ETF seeing a net inflow of 1.399 billion yuan on the same date [10] - From January 14 to February 2, 2023, stock-type ETFs experienced a cumulative net outflow exceeding 830 billion yuan, while some thematic ETFs attracted over 10 billion yuan each [10][11] Group 3 - The number of ETFs with assets exceeding 100 billion yuan has significantly decreased, with only three ETFs surpassing this threshold as of February 2, 2023 [11] - The market outlook suggests that sectors such as AI, solid-state batteries, robotics, and innovative pharmaceuticals are expected to present investment opportunities, with AI being a key focus area for 2026 [12]

Core Viewpoint - The board of directors of Heng Rui Medicine has announced a postponement of the board election, extending the terms of the current board members and senior management until February 1, 2026, to ensure governance stability and avoid disruptions in research and commercialization processes [1][7][16]. Group 1: Board and Management Changes - The current board of directors, including key executives such as Chairman Sun Piaoyang and President Dai Hongbin, will continue their roles until the new board is elected [3][12]. - The postponement of the board election may be influenced by factors such as strategic continuity, shareholder opinion coordination, and candidate selection [7][16]. - As of February 3, 2023, Heng Rui Medicine's A-share price was 57.47 yuan, with a market capitalization of 381.44 billion yuan, while its Hong Kong stock price was 67 HKD, with a market capitalization of 444.69 billion HKD [7][16]. Group 2: Financial Performance and Business Development - In the first three quarters of 2024 and 2025, Heng Rui Medicine reported revenues of 27.985 billion yuan and 23.188 billion yuan, representing year-on-year growth of 22.63% and 14.85%, respectively [8][17]. - The net profits for the same periods were 6.337 billion yuan and 5.751 billion yuan, with year-on-year increases of 47.28% and 24.50% [8][17]. - The company achieved significant revenue from its innovative drug business, with sales and licensing income of 9.561 billion yuan in the first half of 2025, accounting for 60.66% of total revenue [9][18]. Group 3: Market Position and Competitive Landscape - Despite strong growth, Heng Rui Medicine faces challenges from competitors, particularly in the innovative drug sector, where it must contend with similar products from other companies [10][21]. - The company’s overseas revenue was approximately 716 million yuan in 2024, constituting only 2.86% of total revenue, highlighting a significant gap compared to competitors like BeiGene, which had over 60% of its revenue from international markets [9][18]. - The oncology segment remains the largest revenue source for Heng Rui Medicine, generating approximately 14.587 billion yuan in 2024, with a gross margin of 92.57% [19][20].

Core Viewpoint - The pharmaceutical sector is experiencing a mixed performance in 2025, with a significant number of companies forecasting profit increases, while others are facing substantial losses. Group 1: Profit Forecasts - A total of 283 pharmaceutical stocks have disclosed their 2025 earnings forecasts, with 160 companies expecting year-on-year profit growth. Among these, Sino Medical has the highest projected increase, with an expected profit growth of over 32 times [1][4]. - WuXi AppTec is anticipated to achieve a record net profit of 19.15 billion yuan, marking the highest since its listing. This includes nearly 5.6 billion yuan in non-recurring gains from the sale of equity interests [6]. - Sino Medical's projected net profit for 2025 is between 43 million and 50 million yuan, reflecting a year-on-year increase of 2,767% to 3,233%. The growth is attributed to stable revenue from its neuro-interventional business and a 22% increase in its coronary intervention business due to the implementation of a national procurement policy [4][5]. Group 2: Loss Forecasts - Over 120 companies are forecasting profit declines for 2025, with 39 facing their first losses since going public, including companies like Zhifei Biological and Zhenbao Island. Zhifei is expected to report a loss of between 10.698 billion and 13.726 billion yuan, a decline of 630% to 780% compared to the previous year [2][8]. - Zhenbao Island anticipates a net loss of between 1.012 billion and 1.173 billion yuan, attributed to delays in the procurement process and increased cost control measures [8]. - Huiyu Pharmaceutical's losses are primarily due to non-core investment losses, with a fair value loss of 173 million yuan from its investment in Zhejiang Tongyuan Kang Pharmaceutical [9]. Group 3: Innovative Drug Companies - The innovative drug sector is showing signs of recovery, with companies like Nocera and Rongchang Biopharma expected to turn losses into profits. Nocera forecasts a net profit of approximately 633 million yuan, a significant increase from the previous year [3][11]. - Rongchang Biopharma is also expected to achieve profitability with projected revenues of around 3.25 billion yuan, a year-on-year increase of about 89% [11]. - Companies like Junshi Biosciences are reducing their losses significantly, with an expected net loss of around 873 million yuan, a reduction of 408 million yuan compared to the previous year [11][12].

行 业 研 究 / 医 药 生 物 / 证 券 研 究 报 医药生物行业周报 《药品管理法实施条例》全面修订，推 动医药产业创新与监管升级 2026 年 02 月 03 日 【行情回顾】 【本周观点】 【风险提示】 医药行业政策风险；研发进展不及预期风险；业绩不及预期风险 挖掘价值 投资成长 强于大市（维持） 东方财富证券研究所 证券分析师：何玮 证书编号：S1160517110001 证券分析师：崔晓倩 《医药零售高质量发展政策发布，行业有 望加速整合利好龙头》 2026.01.27 《J.P. Morgan 健康大会召开，中国创新药 企扬帆出海》 2026.01.20 《聚焦脑机接口与小核酸药物，JPM 盛会 前奏下医疗布局新浪潮》 2026.01.14 《创新浪潮涌动下，医药板块修复与突破 之路》 证书编号：S1160525080001 相对指数表现 -10% 0% 10% 20% 30% 40% 2025/2 2025/8 2026/2 医药生物 沪深300 相关研究 2025.12.15 《医药生物行业 2025 年三季报财报总结： 业绩分化，医疗设备板块显现拐点》 2025.11.13 告 本周( ...

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strong focus on innovative vaccine development and a commitment to expanding its product pipeline in the biopharmaceutical sector [2][3]. Group 1: Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Advanced Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. - Junshi Biosciences has a complete industry chain capability from drug discovery and development to large-scale production and commercialization, aiming to become a globally positioned innovative pharmaceutical company [3]. Group 2: Product Pipeline and Innovations - The core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and an additional supplemental NDA under review, showcasing the company's strong market presence [3]. - The company’s self-developed Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III registration clinical studies and multiple Phase Ib/II studies in progress [3]. - Junshi Biosciences is exploring early-stage pipelines, with several products expected to initiate critical registration clinical trials by 2025 [3]. Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% year-on-year growth [9]. - The company’s main business revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services and others [9]. Group 4: Market Position and Shareholder Information - As of September 30, 2025, Junshi Biosciences had 35,900 shareholders, an increase of 15.17% from the previous period, with an average of 21,361 circulating shares per person, a decrease of 12.96% [9]. - The company is part of the pharmaceutical and biotechnology sector, focusing on biopharmaceuticals, including COVID-19 drugs, monkeypox concepts, viral prevention, and precision medicine [9].

来源：新浪证券-红岸工作室 2、根据2024年年报，公司海外营收占比为62.85%，受益于人民币贬值。 创新药+人民币贬值受益 1、2025年6月13日互动易：公司是一家全球领先的肿瘤创新治疗公司，为全世界癌症患者研发创新抗肿 瘤药物，提升药物可及性和可负担性。 区间今日近3日近5日近10日近20日主力净流入-1725.95万-1.06亿-1.01亿-2.03亿-4.70亿 主力持仓 2月3日，百济神州涨1.64%，成交额6.51亿元，换手率2.08%，总市值4212.21亿元。 异动分析 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-1725.95万，占比0.03%，行业排名145/158，连续3日被主力资金减仓；所属行业主力净 流入1.41亿，当前无连续增减仓现象，主力趋势不明显。 该股筹码平均交易成本为290.91元，近期筹码减仓，但减仓程度减缓；目前股价靠近压力位273.67，谨 防压力位处回调，若突破压力位则可能会开启一波上涨行情。 公司简介 资料显示，百济神州有限公司位于北京市昌平区中关村生命科学园科学园路30号，成立日期2010年10 ...

普美希替尼有望成为全球首款鼻喷JAK抑制剂 本文为IPO早知道原创 作者｜ 罗宾 微信公众号｜ipozaozhidao 本文由公众号IPO早知道（ID：ipozaozhidao）原创撰写，如需转载请联系C叔↓↓↓ 据IPO早知道消息，近日，普祺医药宣布，已与济川药业集团有限公司（下称"济川药业"）正式订立 合作协议，双方就1类创新药普美昔替尼鼻喷雾剂达成战略合作。根据协议条款，普祺医药将获得最 高1亿元人民币的交易对价，其中首付款4000万元，里程碑付款最高6000万元。济川药业将获得该 产品在大中华区（含大陆、香港、澳门和台湾地区）的独家商业化权益。 此次合作将进一步强化普祺医药在免疫/炎症性疾病创新药的管线布局，并加速该产品的临床推进、 适应症拓展以及商业化落地，推动全新、突破性疗法更快的惠及患者。 普祺医药董事长兼总经理李雨亮表示："我们期待与济川药业缔结伙伴关系，为更多患者带来高质量 的创新药。普美昔替尼鼻喷雾剂在过敏性鼻炎治疗方面，具有显著的差异化优势。我们对未来合作充 满信心，期待在双方团队的共同努力下取得更大的成就。" 济川药业总经理曹伟表示："很高兴与普祺医药达成战略合作，济川药业聚焦中长期发 ...

Core Viewpoint - Yipinhong's stock price has shown a slight increase of 0.18% year-to-date, but has experienced significant declines over various time frames, indicating potential volatility in the stock performance [2]. Group 1: Stock Performance - On February 3, Yipinhong's stock rose by 2.00%, reaching a price of 33.61 CNY per share, with a trading volume of 1.24 billion CNY and a turnover rate of 0.89%, resulting in a total market capitalization of 15.181 billion CNY [1]. - The stock has decreased by 5.03% over the last five trading days, 6.35% over the last 20 days, and 31.24% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Yipinhong reported a revenue of 814 million CNY, reflecting a year-on-year decrease of 34.35%, while the net profit attributable to shareholders was -136 million CNY, showing a year-on-year increase of 44.80% [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million CNY in dividends, with 151 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of January 31, the number of Yipinhong's shareholders reached 30,500, an increase of 14.93% from the previous period, with an average of 13,705 circulating shares per shareholder, a decrease of 12.99% [2]. - Notable new shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several mutual funds entering the top ten circulating shareholders [3].